trending Market Intelligence /marketintelligence/en/news-insights/trending/QPxTG3aXZaoeVRmUGqEMwA2 content esgSubNav
In This List

Roche's test gets FDA nod for detecting 2 more sexually transmitted diseases

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Roche's test gets FDA nod for detecting 2 more sexually transmitted diseases

The U.S. Food and Drug Administration expanded the use of Roche Holding AG's cobas test for use in cobas 6800/8800 Systems to detect two additional sexually transmitted diseases.

The Switzerland-based pharmaceutical giant's test can now be used for detecting trichomonas vaginalis, the most common nonviral sexually transmitted infection in the world. It is also approved to detect Mycoplasma genitalium, a sexually transmitted bacterium that lives on the skin cells of the urinary and genital tracts in humans. The test can detect the diseases in patients irrespective of whether they show any symptoms or not.

The test was previously approved to detect chlamydia and gonorrhea on the cobas 6800/8800 systems.

Roche said in a May 23 press release that the test now provides the flexibility to process up to four sexually transmitted infections from one patient sample.

In the U.S., the cobas 6800/8800 systems are also used for viral load monitoring tests for HIV and hepatitis B virus, among other diseases.